| Quantitative systems pharmacology modeling of acid sphingomyelinase deficiency and the enzyme replacement therapy olipudase alfa is an innovative tool for linking … CD Kaddi, B Niesner, R Baek, P Jasper, J Pappas, J Tolsma, J Li, ... CPT: Pharmacometrics & Systems Pharmacology 7 (7), 442-452, 2018 | 27 | 2018 |
| A quantitative systems pharmacology model of Gaucher disease type 1 provides mechanistic insight into the response to substrate reduction therapy with eliglustat R Abrams, CD Kaddi, M Tao, RJ Leiser, G Simoni, F Reali, J Tolsma, ... CPT: pharmacometrics & systems pharmacology 9 (7), 374-383, 2020 | 17 | 2020 |
| A quantitative systems pharmacology platform to investigate the impact of alirocumab and cholesterol-lowering therapies on lipid profiles and plaque characteristics JE Ming, RE Abrams, DW Bartlett, M Tao, T Nguyen, H Surks, K Kudrycki, ... Gene Regulation and Systems Biology 11, 1177625017710941, 2017 | 15 | 2017 |
| Integrated quantitative systems pharmacology (QSP) model of lysosomal diseases provides an innovative computational platform to support research and therapeutic development for … C Kaddi, F Reali, L Marchetti, B Niesner, S Parolo, G Simoni, S Zaph, ... Molecular Genetics and Metabolism 123 (2), S73-S74, 2018 | 8 | 2018 |
| Development of a quantitative systems pharmacology model to explore hemostatic equivalency of antithrombin lowering C Kaddi, M Tao, R Leiser, A Salvador, S Kattula, P Bhagunde, ... Blood 140 (Supplement 1), 5606-5607, 2022 | 3 | 2022 |
| A robust computational pipeline for model-based and data-driven phenotype clustering G Simoni, C Kaddi, M Tao, F Reali, D Tomasoni, C Priami, K Azer, ... Bioinformatics 37 (9), 1269-1277, 2021 | 3 | 2021 |
| Quantitative systems pharmacology (QSP) analysis predicts that olipudase alfa treatment of patients with extreme acid sphingomyelinase deficiencies can result in meaningful … RJ Leiser, M Tao, C Kaddi, J Li, C Ortemann-Renon, M Kumar, A Jessel, ... Molecular Genetics and Metabolism 138 (2), 107198, 2023 | | 2023 |
| Mechanism-guided analysis of avalglucosidase alfa efficacy on key biomarkers and clinical endpoints in late-onset Pompe disease patients C Kaddi, M Tao, S Bergeler, R Leiser, M Walker, H Geerts, K George, ... Molecular Genetics and Metabolism 138 (2), 107174, 2023 | | 2023 |
| Pediatric and adult acid sphingomyelinase deficiency (ASMD) patients exhibit mechanistic similarity in their disease and response to olipudase alfa M Tao, RJ Leiser, C Kaddi, B Niesner, J Li, C Ortemann-Renon, M Kumar, ... Molecular Genetics and Metabolism 138 (2), 107334, 2023 | | 2023 |
| Quantitative Systems Pharmacology Model of Sickle Cell Disease and Response to Gene Editing Therapy to Support Clinical Development of SAR445136 (BIVV003) C Kaddi, D Holz, M Tao, I Galeon, D Reiner, P Rendo, S Zaph Blood 138, 1860, 2021 | | 2021 |
